ALPHA ANOMERIC

Alpha Anomeric was founded in February 2018 to develop and commercialize its new proprietary alpha anomeric bicyclo DNA platform in in-house development programs as well as in partnership with academia and industry... Alpha Anomeric are developing the next generation of genetic medicines for severe neuromuscular diseases. Our mission is to Provide the precision tools to modulate the wealth of new RNA targets.

Also known as: Alpha Anomeric SAS

Primary location: Paris France